RS BioTherapeutics

RS BioTherapeutics

Early Stage

Novel Solutions for Lung Diseases

Novel Solutions for Lung Diseases

Overview

Raised to Date: Raised: $159,397

Total Commitments ($USD)

Platform

StartEngine

Start Date

04/29/2024

Close Date

07/29/2024

Min. Goal
$10,000
Max. Goal
$1,235,000
Min. Investment

$500

Security Type

Convertible Note

SEC Filing Type

RegCF    Open SEC Filing

Valuation Cap

$40,000,000

Discount

15%

Rolling Commitments ($USD)

Status

Active

Reporting Date

05/17/2024

Days Remaining

72

% of Min. Goal

1,594%

% of Max. Goal

13%

Likelihood of Max
unlikely
Avg. Daily Raise

$8,855

# of Investors

61

Momentum
cool.svg
Create a free account today to gain access to KingsCrowd analytics.
Year Founded

2021

Industry

Healthcare & Pharmaceuticals

Tech Sector

HealthTech

Location

Cumberland, Maryland

RS BioTherapeutics, with a valuation of $40 million, is raising funds on StartEngine. The company is bringing innovation in respiratory drug development to address inflammatory lung diseases. RS BioTherapeutics is initially focused on COPD and IPF with its innovative inhaled therapy, RSBT-001, and is opening new avenues for treatment and care. RSBT-001 is a multi-targeted immune modulator derived from cannabinoids and does not carry the side effects of using corticosteroids for targeting lung inflammation. Dean Hart founded RS BioTherapeutics in February 2021. The current crowdfunding campaign has a minimum target of $10,000 and a maximum target of $1.24 million. The campaign proceeds will be used for product development, safety and toxicology study design, and operations.

Summary Profit and Loss Statement

FY 2023 FY 2022

Revenue

$0

$0

COGS

$0

$0

Tax

$0

$0

 

 

Net Income

$-3,047,449

$-2,083,273

Summary Balance Sheet

FY 2023 FY 2022

Cash

$4,979

$1,502,397

Accounts Receivable

$0

$0

Total Assets

$31,300

$1,527,085

Short-Term Debt

$1,051,533

$1,025,615

Long-Term Debt

$10,104

$24,056

Total Liabilities

$1,061,637

$1,049,671

Financials as of: 04/29/2024
Create a free account today to gain access to KingsCrowd analytics.

Upgrade to gain access

Pay Monthly
Annually (Save 17%)

Edge

$25 /month
billed annually
Free portfolio tracking, data-driven ratings, AI analysis and reports
Plan Includes:
Everything in Free, plus
Company specific KingsCrowd ratings and analyst reports
Deal explorer and side-by-side comparison
Startup exit and failure tracking
Startup market filters and historical industry data
Advanced company search ( with ratings)
Get Edge Annual
Already a member? Log in here.
Founders: enhance your startup's credibility on KingsCrowd. Create an account to claim this raise page.
Add to portfolio
RS BioTherapeutics on StartEngine 2024
Platform: StartEngine
Security Type: Convertible Note
Valuation: $40,000,000

Follow company

Follow RS BioTherapeutics on StartEngine 2024

Buy RS BioTherapeutics's Deal Report

RS BioTherapeutics Deal Report

Get KingsCrowd’s comprehensive report on RS BioTherapeutics including:

  • How our proprietary algorithm rates their current capital raise (1-5 stars)
  • Detailed price, market, team, differentiators, performance, and risk ratings
  • Whether RS BioTherapeutics is undervalued or overvalued
  • Scores on the founding team and key personnel's background and expertise

Buy the RS BioTherapeutics deal report for only $10!

Email address:
Looking to buy more than one deal report? Get unlimited reports by upgrading to Edge